Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma

Photodermatology Photoimmunology and Photomedicine

Volumn 23, Issue 5, 2007, Pages 163-171

  Miller, Janine D ^a,b   Kirkland, Eugene B ^a   Domingo, Diana Santo ^a,b   Scull, Heather ^a,b   Jekutis, Bernadette ^a,b   Dallas, Marcia ^a,b   Cooper, Kevin D ^a,b   Baron, Elma D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

CTCL; Extracorporeal photopheresis; Review

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEXAROTENE; ETRETIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; METHOTREXATE; PSORALEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOID; STEROID;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE TITRATION; ELECTRON THERAPY; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; IRRADIATION; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

HUMANS; LYMPHOMA, T-CELL; PHOTOPHERESIS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34548414566     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2007.00300.x     Document Type: Review

References (59)

1. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
3. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
4. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: From alibert to WHO-EORTC. J Cutan Pathol 2006; 33 (Suppl. 1): 18-26.
5. Slater DN. The new world health organization-European organization for research and treatment of cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005; 153: 874-880.
6. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063.
7. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132: 1309-1313.
8. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26-32.
9. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1485-1507.
10. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: A report of a workshop of the British photodermatology group and the U.K. skin lymphoma group. Br J Dermatol 2006; 154: 7-20.
11. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. preliminary results. N Engl J Med 1987; 316: 297-303.
12. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-945.
13. Demierre MF, Foss FM, Koh HK. Proceedings of the international consensus conference on cutaneous T-cell lymphoma (CTCL) treatment recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994. J Am Acad Dermatol 1997; 36: 460-466.
14. Gollnick HP, Owsianowski M, Ramaker J, Chun SC, Orfanos CE. Extracorporeal photopheresis - a new approach for the treatment of cutaneous T cell lymphomas. Recent Results Cancer Res 1995; 139: 409-415.
15. Knobler E, Warmuth I, Cocco C, Miller B, Mackay J. Extracorporeal photochemotherapy - the Columbia presbyterian experience. Photodermatol Photoimmunol Photomed 2002; 18: 232-237.
16. Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: Yesterday, today, and tomorrow. Hematol Oncol Clin North Am 2003; 17: 1391-1403.
17. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-433.
18. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-1060.
19. Foss FM. New insights into the mechanism of action of extracorporeal phototherapy. Transfusion 2006; 46: 6-8.
20. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003; 29: 61-70.
21. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235-242.
22. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003; 28: 81-89.
23. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846-850.
24. Miracco C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study. Br J Dermatol 1997; 137: 549-557.
25. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: Clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999; 4: 85-90.
26. Stevens SR, Baron ED, Masten S, Cooper KD. Circulating CD4+CD7- lymphocyte burden and rapidity of response: Predictors of outcome in the treatment of sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Arch Dermatol 2002; 138: 1347-1350.
27. Russell-Jones R. Shedding light on photopheresis. Lancet 2001; 357: 820-821.
28. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107: 707-711.
29. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002; 99: 2929-2939.
30. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg 2003; 7: 3-7.
31. Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1990; 23: 898-902.
32. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution. J Am Acad Dermatol 2000; 43: 263-271.
33. Child FJ, Mitchell TJ, Whittaker SJ, Scarisbrick JJ, Seed PT, Russell-Jones R. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clin Exp Dermatol 2004; 29: 231-236.
34. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-579.
35. Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 1997; 92: 99-103.
36. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-957.
37. Wollina U, Liebold K, Kaatz M, Looks A, Stuhlert A, Lange D. Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep 2000; 7: 1197-1201.
38. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma - the Dusseldorf and Munich experience. Arch Dermatol Res 1995; 287: 621-626.
39. Rubegni P, De Aloe G, Fimiani M. Extracorporeal photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma. Br J Dermatol 2000; 143: 894-896.
40. Wollina U, Looks A, Meyer J, et al. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: A prospective controlled trial. Ann NY Acad Sci 2001; 941: 210-213.
41. Konstantinow A, Balda B-R. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Europ Acad Dermatol Vener 1997; 9: 111-117.
42. Vonderheid EC, Zhang Q, Lessin SR, et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-220.
43. Russell-Jones R. Shedding light on photopheresis. Lancet 2001; 357: 820-821.
44. Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: A prospective controlled trial. J Am Acad Dermatol 2001; 44: 253-260.
45. Zouboulis CC, Schmuth M, Doepfmer S, Dippel E, Orfanos CE. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+T lymphocytes. Dermatology 1998; 196: 305-308.
46. Heald PW, Perez MI, Christensen I, Dobbs N, McKiernan G, Edelson R. Photopheresis therapy of cutaneous T-cell lymphoma: The yale-new haven hospital experience. Yale J Biol Med 1989; 62: 629-638.
47. Koh HK, Davis BE, Meola T, Lim HW. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T cell lymphoma (CTCL). J Invest Dermatol 1994; 2: 260.
48. Khabie N, Sherris D, Strome S. Soft tissue alternatives in head and neck reconstruction: Recent developments in bioengineering. Curr Opin Oto HNS 2000; 8: 314-317.
49. Zic J, Arzubiaga C, Salhany KE, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27: 729-736.
50. Demierre MF, Foss FM, Koh HK. Proceedings of the international consensus conference on cutaneous T-cell lymphoma (CTCL) treatment recommendations. Boston, Massachusetts, oct. 1 and 2, 1994. J Am Acad Dermatol 1997; 36: 460-466.
51. Morales MM, Putcha V, Evans HS, Olsen J, Llopis A, Moller H. Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 2005; 211: 325-329.
52. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89: 1240-1244.
53. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States. Cancer 1999; 85: 208-212.
54. Lombardi T, Samson J, Plantier F, Husson C, Kuffer R. Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med 2004; 33: 115-120.
55. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.
56. Heinzelmann P, Kvedar J. Understanding clinical outcomes and indicators associated with telemedicine/telehealth intervention. Telemed and E Health.
57. Sengelmann R, Tull S. Dermal fillers. Available at: http://www.emedicine.com/derm/topic515.htm#section~bibliography2005.
58. Illouz YG. The fat cell "graft", a new technique to fill depressions. 78:122-3. Plast Reconstr Surg 1986; 78: 122-123.
59. Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann NY Acad Sci 2001; 941: 123-138.